Obesity

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial saturation, access, and long-term care distinct from other parts of the world.

Self-paying patients can now obtain semaglutide at a lower cost through trusted telehealth providers.

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the need for equitable treatment strategies.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.

Sleep duration and sleep pattern score were both independently associated with obesity occurrence, and there was a nonlinear relationship between obesity and sleep duration.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Findings from the interviews offer insight into potential strategies for reducing binge eating among patients who experience food insecurity.

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.

Expanding coverage and access to glucagon-like peptide-1 (GLP-1) medication can be beneficial for all with the cooperation of multiple parties in health care.

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising rates of type 2 diabetes and obesity.

The high cost of incretin mimetics for weight management limits insurance coverage and potentiates variation in utilization management strategies to control near-term spending.

The Commission proposed using new measures beyond body mass index (BMI) to define when obesity is a disease.

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

The top content from the Institute for Value-Based Medicine® (IVBM®) highlighted innovative approaches to improving care delivery, addressing obesity, and tackling health inequities across various disciplines.

In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.

GLP-1 drugs are remarkably effective at addressing obesity, cardiovascular, and metabolic conditions, but investigators continue to search for solutions that address the root cause of these disorders.

The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.

The mean body mass index (BMI) and the prevalence of obesity both dropped in 2023 for the first time in more than a decade.

Tirzepatide and semaglutide, both medications for obesity treatment, demonstrate similar safety and efficacy but tirzepatide resulted in greater levels of weight loss among patients compared with semaglutide.

A proposal from the Biden administration to provide coverage of weight loss drugs through Medicaid and Medicare may cost more than it saves.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public health strategies.

Two doses of vitamin D were investigated for their potential to have a positive impact on systolic and diastolic blood pressures when administered in conjunction with calcium.

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began semaglutide treatment.

Combining a digital intervention with health behavior counseling improved weight trajectories and lowered obesity risk in racially and ethnically diverse children over 24 months.